<DOC>
	<DOCNO>NCT00449280</DOCNO>
	<brief_summary>The goal study determine whether significant pharmacokinetic interaction exist rapamycin sorafenib . This study also look toxicity combination rapamycin sorafenib antitumor activity combination subject advance cancer .</brief_summary>
	<brief_title>Drug Interaction Study Sorafenib Rapamycin Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Solid cancer curative measure fail know superior treatment ECOG performance status 02 Measurable nonmeasurable disease Life expectancy great 12 week anticipate need antineoplastic therapy next 4 week Age 18 year old Patients must adequate organ marrow function define : ALT AST less equal 2.5 x ULN ( &lt; 5 x ULN patient liver involvement ) . hemoglobin great equal 9 g/dL absolute neutrophil count great equal 1,500/μL platelet great equal 100,000/μL ( great equal 35,000/μL without transfusion patient CLL/SLL follicular lymphoma ) total bilirubin less equal 1.5 x ULN creatinine less equal 1.5 x ULN Women childbearing potential must negative pregnancy test within 7 day start treatment . Ability understand willingness sign write informed consent document Must evidence bleed diathesis . Patients chemotherapy immunotherapy within 3 week radiotherapy within 14 day prior enter study Patients may receive investigational agent concomitant antineoplastic therapy Patients uncontrolled brain metastasis . Concurrent illness medication exclusion HIVpositive patient receive combination antiretroviral therapy exclude study possible pharmacokinetic interaction sorafenib rapamycin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>metastatic</keyword>
	<keyword>advanced disease</keyword>
	<keyword>phase I</keyword>
</DOC>